Variety of drugs top ibuprofen for migraine
Triptan, ergot and anti-emetic medications appear to be two to five times more effective than ibuprofen for treating migraine, researchers reported on Nov. 29, 2023 in Neurology. “There… read more.
Triptan, ergot and anti-emetic medications appear to be two to five times more effective than ibuprofen for treating migraine, researchers reported on Nov. 29, 2023 in Neurology. “There… read more.
How do emergency department staff determine whether older adults who have fallen need imaging? A new decision rule will help emergency department physicians determine which older adults need… read more.
New research indicates that acoustic stimulation of the brain may ease persistent symptoms in individuals who experienced mild traumatic brain injury in the past. The study, which is… read more.
Migraine is more than just a headache. Often the pain is accompanied by nausea, vomiting, light sensitivity, and sound sensitivity. Chronic migraine can be disabling and may prevent… read more.
Nearly one in five school-aged children and preteens now take melatonin for sleep, and some parents routinely give the hormone to preschoolers, according to new research from the University of… read more.
Hormonal contraceptives taken by adolescents may influence development of the brain in a way that alters the recognition of risks, a new study in rats suggests. Scientists at… read more.
Otsuka Pharmaceutical has filed its antipsychotic agent Rexulti (brexpiprazole) in Japan for a label expansion into agitation associated with dementia due to Alzheimer’s disease. If approved, it would… read more.
Research published in the European Journal of Neurology indicates that COVID-19 and COVID-19 vaccination have negligible effects on migraine severity. Among 550 adults who had received migraine-related care at a… read more.
Among patients with treatment resistant epilepsy, the investigative drug XEN1101 has reduced seizure frequency by over 50%. And in some patients it stops them completely. Researchers reported these… read more.
Neurelis, Inc., announced additional findings from the post hoc analysis of the long-term phase III safety study of Valtoco (diazepam nasal spray) in a pediatric population, aged 6-17… read more.
A UCSF telecare program that improves outcomes for patients with dementia and lightens the load for unpaid caregivers also has the surprising bonus of cutting Medicare costs, according… read more.
Sandoz, a global leader in generic and biosimilar medicines, announced that the European Commission (EC) granted marketing authorization for the first and only biosimilar Tyruko (natalizumab), developed by… read more.
Advertisment